Company expects to finalize Phase 3 trial design for vopimetostat combo in pancreatic cancer in 2H 2026
Tango plans to present Phase 1/2 vopimetostat combo data at 2026 ESMO Congress in October
Company expects cash position to fund planned development and commercialization preparation
Key details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Loss Per Share
$0.37
Q2 Net Loss
$55.34 mln
Q2 Loss Per Basic Share
$0.37
Q2 Operating Expenses
$59.79 mln
Q2 Operating Income
-$59.79 mln
Analyst coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 12 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Tango Therapeutics, Inc. is $40.00, about 44.6% above its August 10 closing price of $27.67
TNGX•
